196 related articles for article (PubMed ID: 29800739)
1. The use of low molecular weight protamine to enhance oral absorption of exenatide.
Zhang L; Shi Y; Song Y; Sun X; Zhang X; Sun K; Li Y
Int J Pharm; 2018 Aug; 547(1-2):265-273. PubMed ID: 29800739
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery system for low molecular weight protamine-dextran-poly(lactic-co-glycolic acid) carrying exenatide to overcome the mucus barrier and improve intestinal targeting efficiency.
Song Y; Shi Y; Zhang L; Hu H; Zhang C; Yin M; Zhang X; Sun K
Nanomedicine (Lond); 2019 Apr; 14(8):989-1009. PubMed ID: 31088322
[No Abstract] [Full Text] [Related]
3. Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates.
Sheng J; He H; Han L; Qin J; Chen S; Ru G; Li R; Yang P; Wang J; Yang VC
J Control Release; 2016 Jul; 233():181-90. PubMed ID: 27178809
[TBL] [Abstract][Full Text] [Related]
4. Tf ligand-receptor-mediated exenatide-Zn
Zhang L; Shi Y; Song Y; Duan D; Zhang X; Sun K; Li Y
J Drug Target; 2018 Dec; 26(10):931-940. PubMed ID: 29619854
[TBL] [Abstract][Full Text] [Related]
5. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach.
Soudry-Kochavi L; Naraykin N; Nassar T; Benita S
J Control Release; 2015 Nov; 217():202-10. PubMed ID: 26381898
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
[TBL] [Abstract][Full Text] [Related]
7. Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block copolymer: potential implications on diabetic nephropathy.
Tong F
Int J Nanomedicine; 2017; 12():4663-4678. PubMed ID: 28721043
[TBL] [Abstract][Full Text] [Related]
8. Bioinspired butyrate-functionalized nanovehicles for targeted oral delivery of biomacromolecular drugs.
Wu L; Liu M; Shan W; Zhu X; Li L; Zhang Z; Huang Y
J Control Release; 2017 Sep; 262():273-283. PubMed ID: 28774842
[TBL] [Abstract][Full Text] [Related]
9. Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice.
Shi Y; Sun X; Zhang L; Sun K; Li K; Li Y; Zhang Q
Sci Rep; 2018 Jan; 8(1):726. PubMed ID: 29335533
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of CSK-DEX-PLGA Nanoparticles for the Oral Delivery of Exenatide to Improve Its Mucus Penetration and Intestinal Absorption.
Song Y; Shi Y; Zhang L; Hu H; Zhang C; Yin M; Chu L; Yan X; Zhao M; Zhang X; Mu H; Sun K
Mol Pharm; 2019 Feb; 16(2):518-532. PubMed ID: 30601014
[TBL] [Abstract][Full Text] [Related]
11. Exendin-4 Loaded Nanoparticles with a Lipid Shell and Aqueous Core Containing Micelles for Enhanced Intestinal Absorption.
Chen C; Zhu X; Dou Y; Xu J; Zhang J; Fan T; Du J; Liu K; Deng Y; Zhao L; Huang Y
J Biomed Nanotechnol; 2015 May; 11(5):865-76. PubMed ID: 26349398
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
[TBL] [Abstract][Full Text] [Related]
13. The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.
Li X; Wang C; Liang R; Sun F; Shi Y; Wang A; Liu W; Sun K; Li Y
Pharm Res; 2015 Mar; 32(3):1017-27. PubMed ID: 25270570
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation.
Chen C; Zheng H; Xu J; Shi X; Li F; Wang X
Daru; 2017 Sep; 25(1):20. PubMed ID: 28870261
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
Chuang EY; Nguyen GT; Su FY; Lin KJ; Chen CT; Mi FL; Yen TC; Juang JH; Sung HW
Biomaterials; 2013 Oct; 34(32):7994-8001. PubMed ID: 23891516
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Signatures of the Exenatide Nanoparticles Complex Against Myocardial Ischemia Reperfusion Injury.
Zhang Y; Qian P; Zhou H; Shen R; Hu B; Shen Y; Zhang X; Shen X; Xu G; Jin L
Kidney Blood Press Res; 2018; 43(4):1273-1284. PubMed ID: 30078011
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats.
Li X; Zhao Z; Li L; Zhou T; Lu W
Drug Deliv; 2015 Jan; 22(1):86-93. PubMed ID: 24467493
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.
Li XG; Li L; Zhou X; Chen Y; Ren YP; Zhou TY; Lu W
Acta Pharmacol Sin; 2012 Nov; 33(11):1379-86. PubMed ID: 22659626
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
Lim SM; Eom HN; Jiang HH; Sohn M; Lee KC
J Pharm Sci; 2015 Jan; 104(1):72-80. PubMed ID: 25407390
[TBL] [Abstract][Full Text] [Related]
20. A Nanocomposite Vehicle Based on Metal-Organic Framework Nanoparticle Incorporated Biodegradable Microspheres for Enhanced Oral Insulin Delivery.
Zhou Y; Liu L; Cao Y; Yu S; He C; Chen X
ACS Appl Mater Interfaces; 2020 May; 12(20):22581-22592. PubMed ID: 32340452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
